Regional perfusion for melanoma of the extremities

R. O. Pfefferkorn, M. S. Didolkar

Research output: Contribution to journalArticle

Abstract

A common cause for treatment failure in patients with malignant melanoma is local or regional recurrence of the disease. It is presumed that the poor treatment response rate is due to occult metastases present during the initial treatment phase. In an effort to improve response rate and survival, 15 patients with malignant melanoma of an extremity underwent isolated regional limb perfusion combined with hyperthermia and the cytotoxic drug Imidazole Carboxamide (DTIC). Study objectives include examination of response, subsequent tumor behavior after treatment, and the side effects of hyperthermia on the extremity. The 0-2 year response rate is 100%. None of the patients developed local recurrence, intransit or lymph node metastases, or disseminated tumor. There have been no surgical deaths and only a few patients developed some symptomatology of the known toxic side effects of the chemotherapeutic agent. Our early experience justifies the continued employment of regional hyperthermic chemotherapeutic isolation perfusion as an ideal treatment for patients who have malignant melanoma confined to an extremity.

Original languageEnglish (US)
Pages (from-to)475-479
Number of pages5
JournalJournal of Extra-Corporeal Technology
Volume14
Issue number6
StatePublished - 1982
Externally publishedYes

Fingerprint

Melanoma
Extremities
Perfusion
Fever
Neoplasm Metastasis
Recurrence
Dacarbazine
Poisons
Therapeutics
Treatment Failure
Neoplasms
Survival Rate
Lymph Nodes
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine (miscellaneous)

Cite this

Pfefferkorn, R. O., & Didolkar, M. S. (1982). Regional perfusion for melanoma of the extremities. Journal of Extra-Corporeal Technology, 14(6), 475-479.

Regional perfusion for melanoma of the extremities. / Pfefferkorn, R. O.; Didolkar, M. S.

In: Journal of Extra-Corporeal Technology, Vol. 14, No. 6, 1982, p. 475-479.

Research output: Contribution to journalArticle

Pfefferkorn, RO & Didolkar, MS 1982, 'Regional perfusion for melanoma of the extremities', Journal of Extra-Corporeal Technology, vol. 14, no. 6, pp. 475-479.
Pfefferkorn, R. O. ; Didolkar, M. S. / Regional perfusion for melanoma of the extremities. In: Journal of Extra-Corporeal Technology. 1982 ; Vol. 14, No. 6. pp. 475-479.
@article{e20d612196204236b59317eeb7c9df58,
title = "Regional perfusion for melanoma of the extremities",
abstract = "A common cause for treatment failure in patients with malignant melanoma is local or regional recurrence of the disease. It is presumed that the poor treatment response rate is due to occult metastases present during the initial treatment phase. In an effort to improve response rate and survival, 15 patients with malignant melanoma of an extremity underwent isolated regional limb perfusion combined with hyperthermia and the cytotoxic drug Imidazole Carboxamide (DTIC). Study objectives include examination of response, subsequent tumor behavior after treatment, and the side effects of hyperthermia on the extremity. The 0-2 year response rate is 100{\%}. None of the patients developed local recurrence, intransit or lymph node metastases, or disseminated tumor. There have been no surgical deaths and only a few patients developed some symptomatology of the known toxic side effects of the chemotherapeutic agent. Our early experience justifies the continued employment of regional hyperthermic chemotherapeutic isolation perfusion as an ideal treatment for patients who have malignant melanoma confined to an extremity.",
author = "Pfefferkorn, {R. O.} and Didolkar, {M. S.}",
year = "1982",
language = "English (US)",
volume = "14",
pages = "475--479",
journal = "Journal of Extra-Corporeal Technology",
issn = "0022-1058",
publisher = "American Society of Extra-Corporeal Technology",
number = "6",

}

TY - JOUR

T1 - Regional perfusion for melanoma of the extremities

AU - Pfefferkorn, R. O.

AU - Didolkar, M. S.

PY - 1982

Y1 - 1982

N2 - A common cause for treatment failure in patients with malignant melanoma is local or regional recurrence of the disease. It is presumed that the poor treatment response rate is due to occult metastases present during the initial treatment phase. In an effort to improve response rate and survival, 15 patients with malignant melanoma of an extremity underwent isolated regional limb perfusion combined with hyperthermia and the cytotoxic drug Imidazole Carboxamide (DTIC). Study objectives include examination of response, subsequent tumor behavior after treatment, and the side effects of hyperthermia on the extremity. The 0-2 year response rate is 100%. None of the patients developed local recurrence, intransit or lymph node metastases, or disseminated tumor. There have been no surgical deaths and only a few patients developed some symptomatology of the known toxic side effects of the chemotherapeutic agent. Our early experience justifies the continued employment of regional hyperthermic chemotherapeutic isolation perfusion as an ideal treatment for patients who have malignant melanoma confined to an extremity.

AB - A common cause for treatment failure in patients with malignant melanoma is local or regional recurrence of the disease. It is presumed that the poor treatment response rate is due to occult metastases present during the initial treatment phase. In an effort to improve response rate and survival, 15 patients with malignant melanoma of an extremity underwent isolated regional limb perfusion combined with hyperthermia and the cytotoxic drug Imidazole Carboxamide (DTIC). Study objectives include examination of response, subsequent tumor behavior after treatment, and the side effects of hyperthermia on the extremity. The 0-2 year response rate is 100%. None of the patients developed local recurrence, intransit or lymph node metastases, or disseminated tumor. There have been no surgical deaths and only a few patients developed some symptomatology of the known toxic side effects of the chemotherapeutic agent. Our early experience justifies the continued employment of regional hyperthermic chemotherapeutic isolation perfusion as an ideal treatment for patients who have malignant melanoma confined to an extremity.

UR - http://www.scopus.com/inward/record.url?scp=0020398977&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020398977&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0020398977

VL - 14

SP - 475

EP - 479

JO - Journal of Extra-Corporeal Technology

JF - Journal of Extra-Corporeal Technology

SN - 0022-1058

IS - 6

ER -